Oral sessions summaries

AMR Gonorrhea

The threat of antimicrobial resistant gonorrhea

Henry John Christiaan De Vries, MD, PhD

Expert commentary by Nuno Gomes, MD

EADV Virtual - Oral session

Alopecia Areata

Initial results from a long-term, open-label extension study with CTP-543, an oral janus kinase inhibitor, in patients with moderate to severe alopecia areata

James Cassella, PhD

Expert Commentary by Prof. Bianca Maria Piraccini, MD, PhD

EADV Virtual - Oral session

Alopecia Areata

Emerging therapies for alopecia areata

Antonella Tosti, MD

Expert commentary by Anna Waśkiel-Burnat, MD, PhD

EADV Virtual - Oral session

Atopic Dermatitis

New targeted therapies in atopic dermatitis

Emma Guttman-Yassky, MD, PhD

EADV Virtual - Oral session

Atopic Dermatitis

Safety and Efficacy of Upadacitinib Monotherapy in Adolescents and Adults with Moderate-to-severe Atopic Dermatitis: Results From 2 Pivotal, Phase 3, Randomized, Double-blinded, Monotherapy, Placebo-controlled Studies (Measure Up 1 and Measure Up 2)

Emma Guttman-Yassky, MD, PhD

EADV Virtual - Oral session

COVID-19

Management of COVID-19: The dermatologist’s perspective

Michael Binder, MD

Expert commentary by Mihaela Leventer, MD

EADV Virtual - Oral session

COVID-19

Use of biologics and immunosuppressive drugs in COVID period

Phyllis Spuls, MD, PhD

EADV Virtual - Oral session

Chronic Hand Eczema

A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of gusacitinib (ASN002) in subjects with moderate-to-severe chronic hand eczema

Howard Sofen, MD

Expert commentary by Peter Lio, MD

EADV Virtual - Oral session

Epidermolysis Bullosa

Efficacy and safety of oleogel-S10 for epidermolysis bullosa – Results of 3 months double-blind treatment during the phase 3 study EASE

Dedee Murrell, MD

Expert commentary by Carolina Gouveia, MD

EADV Virtual - Oral session

Hidradenitis Suppurativa

Biologics in the management of hidradenitis suppurativa

Hessel van der Zee, MD, PhD

EADV Virtual - Oral session

JAK Inhibitors

Topical JAK inhibitors

Kamran Ghoreschi, MD

EADV Virtual - Oral session

Melanoma

Combined therapy: What is the future?

Christian Posch, MD, PhD

EADV Virtual - Oral session

Metastatic Melanoma

Immunotherapy in metastatic melanoma

Erika Richtig, MD

Expert commantary by Caroline Robert, MD, PhD

EADV Virtual - Oral session

Scars

Future of medical scar treatment

Peter Velthuis, MD, PhD

Expert commentary by Severin Laeuchli, MD

EADV Virtual - Oral session

cSCC

New management of advanced and metastatic SCC

Clio Dessinioti, MD, PhD

EADV Virtual - Oral session

EADV VIRTUAL HIGHLIGHTS ARE
AVAILABLE ON THE MEDFYLE APP

DOWNLOAD
THE APP

Dermahilights annual meeting and webinars